Ixabepilone is under clinical development by R-Pharm US and currently in Phase II for Epithelial Ovarian Cancer. According to GlobalData, Phase II drugs for Epithelial Ovarian Cancer have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Ixabepilone’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ixabepilone overview
Ixabepilone (Ixempra, Ixemprya) is a microtubule inhibitor and a type of epothilone analog belonging to the class of antineoplastic agents. It is formulated as lyophilized powder for solution for intravenous route of administration. It is indicated for the treatment of metastatic or locally advanced breast cancer, fallopian tube cancer, and primary peritoneal cancers, epithelial ovarian cancer. It is being developed based on DRP platform technology.
It was under development for the treatment of metastatic breast cancer and HER-2 negative breast cancer, HER-2 positive beast cancer, triple-negative breast cancer in EU, epithelial ovarian cancer.
For a complete picture of Ixabepilone’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
